Peptides have become one of the most talked-about categories in weight loss.
Search online and you will see everything from semaglutide and tirzepatide to AOD-9604, CJC-1295, ipamorelin, and retatrutide described as “fat-loss peptides.”
But these compounds are not interchangeable.
Some peptide-based medications have been tested in thousands of people, evaluated in large randomized clinical trials, and approved by the U.S. Food and Drug Administration for chronic weight management.
Others have only preliminary human research.
Some are FDA approved, but for conditions completely unrelated to general weight loss.
And others are being sold online despite having no FDA approval for human use.
That distinction matters.
If your goal is to reduce body fat, improve metabolic health, and preserve muscle, the question should not simply be:
“Which peptide burns the most fat?”
A better question is:
Which treatments actually have evidence for meaningful, sustainable weight reduction, and which claims are still ahead of the science?
Here is what we know as of September 2026.
What Are Peptides?
Peptides are short chains of amino acids.
Your body naturally uses peptide hormones to communicate between tissues and regulate processes including:
- Appetite
- Blood sugar
- Digestion
- Growth hormone signaling
- Reproduction
- Inflammation
- Energy balance
Researchers can also create peptide-based medications that mimic or modify these biological signals.
Some of today’s most effective medications for obesity are peptide-based drugs that act on hormones involved in hunger and satiety.
Semaglutide, for example, acts on the glucagon-like peptide-1, or GLP-1, receptor.
Tirzepatide activates both GLP-1 and glucose-dependent insulinotropic polypeptide, or GIP, receptors.
These are very different from many of the so-called “research peptides” promoted online for fat burning.
The word peptide tells you something about the molecule.
It does not tell you whether the medication has been proven effective.
Which Peptides Are FDA Approved for Weight Loss?
For most adults asking about peptide therapy for weight management, three names are particularly relevant:
| Medication | Brand | FDA Approved for General Weight Management? | Main Pathway |
|---|---|---|---|
| Semaglutide | Wegovy | Yes | GLP-1 |
| Tirzepatide | Zepbound | Yes | GIP + GLP-1 |
| Liraglutide | Saxenda | Yes | GLP-1 |
| Setmelanotide | Imcivree | Only for specific forms of obesity | MC4 receptor |
| Tesamorelin | Egrifta WR | No, not for general weight loss | GHRH |
The current FDA label for Wegovy includes semaglutide injection and oral tablets for weight reduction in appropriate adults, and injectable Wegovy is also approved for adolescents with obesity. In March 2026, the FDA additionally approved a higher-dose 7.2 mg semaglutide injection, Wegovy HD, for weight reduction and long-term weight maintenance in certain adults.
Zepbound is FDA approved for reducing excess body weight and maintaining weight reduction long term in adults with obesity or overweight plus at least one weight-related condition.
Saxenda remains FDA approved for long-term weight reduction in appropriate adults and certain adolescents with obesity.
Let’s look at what the evidence actually shows.
1. Semaglutide: One of the Most Studied Peptides for Weight Loss
Semaglutide is a GLP-1 receptor agonist.
GLP-1 is a hormone naturally released from the gastrointestinal tract after eating. Among other functions, it helps regulate appetite, glucose, insulin secretion, and digestion.
Semaglutide extends the activity of this pathway.
For many patients, this can result in:
- Less hunger
- Increased fullness after meals
- Fewer cravings
- Reduced food intake
- Improved blood glucose regulation
How Much Weight Can Semaglutide Help People Lose?
In the landmark STEP 1 clinical trial, adults with obesity or overweight without diabetes received semaglutide 2.4 mg weekly or placebo along with lifestyle intervention.
After 68 weeks, average body weight decreased by:
14.9% with semaglutide
compared with:
2.4% with placebo.
More than 86% of participants receiving semaglutide lost at least 5% of their starting weight. Approximately half lost at least 15%.
Other STEP trials have reported average weight reductions of approximately 15% to 17% in participants without diabetes.
That is far more evidence than exists for most compounds marketed online as “fat-burning peptides.”
Is Ozempic the Same Thing as Wegovy?
Both contain semaglutide, but their FDA-approved indications and dosing are not identical.
Wegovy is specifically approved for weight reduction and long-term weight management in appropriate patients.
Ozempic is primarily indicated for type 2 diabetes and certain related risk reductions.
The brand and indication matter.
2. Tirzepatide: GIP + GLP-1 Signaling
Tirzepatide is another peptide-based medication with substantial clinical evidence.
Unlike semaglutide, tirzepatide activates two hormonal pathways:
GIP + GLP-1
The weight-loss brand is Zepbound.
Mounjaro also contains tirzepatide, but its primary FDA indication is for type 2 diabetes.
Tirzepatide Weight-Loss Results
In the SURMOUNT-1 trial, more than 2,500 adults with obesity or overweight were treated for 72 weeks.
Average weight reduction was approximately:
- 15.0% with 5 mg
- 19.5% with 10 mg
- 20.9% with 15 mg
- 3.1% with placebo
At the higher doses, approximately half or more of participants lost at least 20% of their starting body weight.
These results helped establish tirzepatide as a major medical treatment option for obesity.
But there is an important distinction:
Weight loss is not automatically the same as fat-only loss.
Do GLP-1 Peptides Actually Reduce Body Fat?
Yes, much of the weight reduction associated with these medications appears to come from fat.
But not all of it.
A body-composition substudy of SURMOUNT-1 used DXA scans to examine participants receiving tirzepatide.
Over 72 weeks, the tirzepatide group experienced average reductions of:
- 21.3% in total body weight
- 33.9% in fat mass
- 10.9% in lean mass
Approximately 75% of the total weight lost was fat mass and 25% was lean mass in the substudy.
That is why a medically supervised weight-loss program should not focus exclusively on making the scale fall as rapidly as possible.
Body composition matters.
The goal should generally be to reduce excess body fat while protecting muscle, strength, nutritional status, and metabolic function.
3. Liraglutide: Effective, but an Older GLP-1 Option
Liraglutide, sold for weight management as Saxenda, was one of the earlier GLP-1 medications approved for chronic weight management.
Unlike semaglutide and tirzepatide, which are typically dosed weekly, Saxenda is administered daily.
In the SCALE Obesity and Prediabetes trial, participants treated with liraglutide lost an average of approximately 8.4 kg after 56 weeks versus 2.8 kg with placebo.
About 63% of liraglutide-treated participants lost at least 5% of their body weight.
Liraglutide clearly works for some patients.
However, newer incretin therapies have generally produced greater average weight reductions in clinical trials.
4. Setmelanotide: FDA Approved, but Not for Typical Obesity
Setmelanotide, sold as Imcivree, is another peptide-based medication capable of producing meaningful weight reduction.
But it is not a general-purpose weight-loss medication.
Setmelanotide acts on the melanocortin-4 receptor pathway and was originally approved for specific rare genetic causes of severe obesity, including certain POMC, PCSK1, and LEPR deficiencies and Bardet-Biedl syndrome.
Its indications have continued to expand.
In 2026, the FDA approved an additional indication for patients aged 4 years and older with acquired hypothalamic obesity.
This is a good example of why saying a peptide is “FDA approved for weight loss” does not tell the entire story.
The approved indication matters.
Most adults struggling with weight after 35 do not have one of these rare conditions.
What About Tesamorelin for Belly Fat?
Tesamorelin is often included in online discussions about peptides and visceral fat.
There is some truth behind the conversation, but the context is frequently lost.
Tesamorelin is a growth hormone-releasing factor analog sold as Egrifta WR.
It is FDA approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy.
However, its prescribing information explicitly states that it is not indicated for weight-loss management.
So:
FDA approved? Yes.
FDA approved as a general fat-loss treatment? No.
Those are very different claims.
What About AOD-9604?
AOD-9604 is frequently marketed as a “fat-burning peptide.”
It is derived from a fragment of human growth hormone and has been promoted with claims that it can stimulate fat breakdown without many of the effects associated with full growth hormone.
The marketing is ahead of the clinical evidence.
AOD-9604 is not an FDA-approved weight-loss medication.
More importantly, FDA has specifically listed AOD-9604 among bulk drug substances that may present significant safety risks when used in compounding.
FDA notes concerns including peptide-related impurities, immune reactions, limited safety information, and reported serious adverse events for which causality remains uncertain.
There is not anything approaching the large Phase 3 obesity evidence available for semaglutide or tirzepatide.
That does not prove that every biological effect attributed to AOD-9604 is impossible.
It means there is currently insufficient evidence to place it in the same category as FDA-approved obesity medications.
What About CJC-1295?
CJC-1295 is a synthetic analog of growth hormone-releasing hormone, or GHRH.
Human studies have shown that CJC-1295 can increase growth hormone and IGF-1 concentrations.
In one early trial involving healthy adults, CJC-1295 produced sustained increases in GH and IGF-1 after administration.
But that trial was not a large obesity treatment study.
Increasing growth hormone signaling is not the same thing as demonstrating clinically meaningful, long-term fat loss.
CJC-1295 is also not FDA approved as a weight-loss medication.
FDA currently lists CJC-1295 among substances with potential significant safety risks in compounding. The agency has cited limited clinical data as well as reported adverse events including increased heart rate and systemic vasodilatory reactions.
So while the biological mechanism may sound appealing, the clinical evidence for obesity does not currently compare with approved incretin therapies.
What About Ipamorelin?
Ipamorelin is a growth hormone secretagogue.
It stimulates growth hormone release through the ghrelin receptor.
Small human studies have shown that ipamorelin can temporarily increase growth hormone secretion.
That has led to claims involving:
- Fat loss
- Muscle development
- Recovery
- Anti-aging
- Improved body composition
But once again, stimulating a hormone does not automatically prove a clinically meaningful outcome.
Ipamorelin has not been established through large obesity trials as an effective chronic weight-loss medication.
FDA has also identified potential safety concerns related to compounded ipamorelin, including insufficient safety data for certain injectable routes and concerns about peptide aggregation, impurities, and immunogenicity.
It is not FDA approved for general weight loss.
What About BPC-157 for Fat Loss?
BPC-157 is frequently grouped with peptides used for recovery, gut health, injury healing, and occasionally fat loss.
There is no established FDA-approved indication for BPC-157 as a weight-loss medication.
FDA has also identified BPC-157 as a substance that may present significant safety risks when compounded and notes that available human safety data are limited.
If your primary goal is meaningful fat reduction, BPC-157 should not be confused with medications that have completed large randomized obesity trials.
Retatrutide: The Peptide Everyone Is Talking About in 2026
Retatrutide deserves its own section because interest has exploded.
Retatrutide is an investigational triple hormone receptor agonist targeting:
- GIP
- GLP-1
- Glucagon
The mechanism has generated significant interest because adding glucagon receptor activity may influence appetite and energy metabolism differently from currently approved dual-agonist medications.
Phase 3 results announced in 2026 have reported substantial weight reduction.
On September 29, 2026, Eli Lilly announced detailed Phase 3 TRIUMPH-2 results in adults with obesity or overweight and type 2 diabetes. The company reported average weight reduction of 20.8% at the 12 mg dose over 80 weeks. These are company-reported Phase 3 findings and detailed peer-reviewed publication remains important for full interpretation.
But here is the critical point:
Retatrutide Is Not FDA Approved
As of September 30, 2026, retatrutide remains an investigational medication and has not been approved by FDA or another regulatory agency.
FDA also states that retatrutide cannot be used in compounding under federal law because it is not a component of an FDA-approved medication and does not meet applicable compounding requirements.
If you see a website currently selling “retatrutide” directly to consumers, that should not be confused with participation in an authorized clinical trial or access to an FDA-approved medication.
Promising research and FDA approval are not the same thing.
FDA Approved vs. Compounded: Another Important Distinction
This is one of the most misunderstood areas of peptide therapy.
A compounded medication is not FDA approved.
That remains true even when the medication is prepared using an ingredient that also appears in an FDA-approved product.
FDA-approved medications undergo premarket evaluation for:
- Safety
- Effectiveness
- Manufacturing quality
- Stability
- Labeling
- Dosing
Compounded drugs do not go through that same FDA approval process.
FDA currently recommends that compounded GLP-1 products be used only when a patient’s medical needs cannot be met by an FDA-approved drug. The agency has also reported dosing errors, quality concerns, fraudulent products, and adverse-event reports involving compounded semaglutide and tirzepatide.
As of May 31, 2026, FDA reported receiving 990 adverse-event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide, while noting that these reports do not by themselves prove that the compounded medication caused each event.
This does not mean every compounded medication is automatically unsafe.
It means patients deserve accurate language about what is and is not FDA approved.
Do Peptides “Melt Fat”?
No medication literally melts fat.
Even highly effective incretin medications primarily work by changing biological signals that influence:
- Hunger
- Satiety
- Food intake
- Gastric emptying
- Insulin and glucose regulation
- Energy balance
Tirzepatide additionally affects GIP signaling.
Future medications such as retatrutide add other pathways.
The ultimate reduction in body fat happens because these physiological changes make a sustained energy deficit easier to achieve and maintain.
That is very different from injecting something that selectively dissolves fat tissue.
Why Losing Weight Is Not Enough
The best weight-loss strategy should improve body composition, not simply generate the lowest possible number on a scale.
Rapid weight loss can involve reductions in both fat mass and lean mass.
Research on incretin medications increasingly emphasizes the importance of combining medical weight management with strategies designed to preserve muscle.
Those strategies may include:
Prioritizing Protein
When appetite decreases dramatically, protein intake can fall unintentionally.
Protein needs vary depending on body size, age, kidney health, training status, calorie intake, and individual goals.
For many adults undergoing active weight loss, higher protein intake than the standard adult minimum may be appropriate.
Resistance Training
Your body needs a reason to retain muscle.
Progressive resistance training provides that stimulus.
Cardio supports cardiovascular health, but strength training deserves a central role when preserving muscle during significant weight reduction.
Monitoring Body Composition
The scale cannot tell you what type of tissue you are losing.
Depending on the individual, tracking waist circumference, strength, training performance, protein intake, and body composition can provide a more complete picture.
Correcting Nutritional Deficiencies
Dramatically reduced food intake can also mean reduced intake of vitamins, minerals, essential fats, fiber, and protein.
The goal is not simply to eat as little as possible.
The goal is to create a sustainable nutritional environment in which fat can come down without unnecessarily compromising health.
What Should Be Evaluated Before Starting Weight-Loss Medication?
Medication selection should be individualized.
A proper evaluation may consider factors such as:
- Current body weight and waist circumference
- Body composition
- Blood pressure
- Fasting glucose
- Hemoglobin A1C
- Insulin resistance
- Lipid profile
- Liver health
- Kidney function
- Thyroid function when clinically indicated
- Medications
- Gastrointestinal history
- Gallbladder history
- Personal and family medical history
- Sleep
- Strength and activity level
- Protein and calorie intake
- Hormonal factors when clinically relevant
For high-achieving adults in their 30s, 40s, and 50s, weight gain may also be occurring alongside changing sleep, stress, recovery, insulin sensitivity, menopause, declining activity, or changes in muscle mass.
Medication can be an important tool.
It should not automatically become the entire strategy.
Are GLP-1 Peptides Safe?
FDA-approved GLP-1 and GIP/GLP-1 medications have substantial safety data, but they are still prescription medications with potential side effects and contraindications.
Common adverse effects can include:
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Abdominal discomfort
- Reduced appetite
More serious risks and precautions can include pancreatitis, gallbladder disease, dehydration-related kidney problems, severe gastrointestinal reactions, and other medication-specific risks.
Semaglutide, tirzepatide, and liraglutide prescribing information also contains boxed warnings involving thyroid C-cell tumors observed in rodents. These medications are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
This is why these medications require proper medical evaluation and supervision.
Peptides for Fat Loss: What Works and What Doesn’t?
Here is the simplest way to look at the current evidence.
Strong Evidence + FDA Approval for General Weight Management
Semaglutide, Wegovy
Extensive Phase 3 obesity data and FDA approval.
Tirzepatide, Zepbound
Extensive Phase 3 obesity data and FDA approval.
Liraglutide, Saxenda
FDA approved with established clinical weight-loss evidence, although average reductions in older trials were generally smaller than those reported with newer incretin therapies.
FDA Approved Only for Specialized Conditions
Setmelanotide, Imcivree
Effective for specific genetic, syndromic, and acquired hypothalamic forms of obesity. Not intended for ordinary polygenic obesity.
Tesamorelin, Egrifta WR
FDA approved to reduce excess abdominal fat in HIV-associated lipodystrophy. Explicitly not approved for general weight-loss management.
Interesting Mechanism but Insufficient Weight-Loss Evidence
CJC-1295
Can increase GH and IGF-1, but large obesity trials demonstrating long-term weight-loss efficacy are lacking.
Ipamorelin
Can stimulate growth hormone secretion, but is not an FDA-approved obesity treatment and lacks the evidence supporting approved incretin medications.
AOD-9604
Often marketed for fat loss but not FDA approved, with limited clinical evidence and FDA-identified safety concerns related to compounding.
BPC-157
Not an FDA-approved fat-loss medication and lacks established obesity-treatment evidence.
Promising but Investigational
Retatrutide
Strong emerging Phase 3 results, but still investigational as of September 30, 2026. It is not FDA approved and FDA states it cannot currently be used in compounding under federal law.
The Bigger Question: What Kind of Weight Are You Losing?
This may ultimately be more important than finding the newest peptide.
Losing 30 pounds while becoming weaker, undernourished, and unable to maintain the result is not the same outcome as losing 30 pounds while improving:
- Waist circumference
- Insulin sensitivity
- Blood pressure
- Strength
- Fitness
- Sleep
- Protein intake
- Body composition
- Metabolic health
Medical weight loss should evolve beyond asking:
“How quickly can we make the scale go down?”
The better question is:
“How can we reduce excess body fat while protecting the muscle, strength, and health you need for the next 20 to 30 years?”
That requires more than a prescription.
The 1st Optimal Approach to Medical Weight Loss
At 1st Optimal, weight management is approached as part of a larger functional health strategy.
That means looking beyond the scale.
Depending on the individual, treatment may involve medical evaluation, laboratory testing, body-composition goals, nutrition, protein intake, resistance training, sleep, recovery, metabolic health, hormone health, and ongoing coaching.
Medication may be appropriate.
But the goal is not simply to suppress appetite indefinitely.
The goal is to use the right tools while building a healthier metabolic environment that can support long-term results.
If GLP-1 or peptide-based weight-loss therapy is being considered, the first step should be determining whether treatment is medically appropriate and which option actually has evidence for your situation.
Frequently Asked Questions About Peptides for Fat Loss
What is the best peptide for fat loss?
There is no single best medication for every person. Among peptide-based medications, semaglutide, tirzepatide, and liraglutide have FDA approval and substantial evidence for chronic weight management in appropriate patients. Tirzepatide and semaglutide have produced particularly large average weight reductions in clinical trials.
Which peptides are FDA approved for weight loss?
For general chronic weight management, FDA-approved peptide or incretin-based medications include semaglutide, tirzepatide, and liraglutide. Setmelanotide is approved for specific rare and hypothalamic forms of obesity rather than typical obesity.
Is AOD-9604 FDA approved for fat loss?
No. AOD-9604 is not FDA approved for weight loss. FDA has also raised safety concerns regarding its use as a bulk substance in compounded medications.
Is CJC-1295 FDA approved for weight loss?
No. CJC-1295 is not an FDA-approved weight-loss medication. Early human research demonstrates effects on growth hormone and IGF-1, but that does not establish long-term obesity-treatment efficacy.
Is ipamorelin FDA approved?
Ipamorelin is not FDA approved as a weight-loss medication. FDA has also identified safety and quality concerns related to its use in compounded products.
Is retatrutide FDA approved in 2026?
No. As of September 30, 2026, retatrutide remains investigational despite promising Phase 3 results. FDA states that retatrutide cannot currently be used for compounding under federal law.
Is compounded semaglutide FDA approved?
No. Compounded medications are not FDA approved and do not undergo FDA’s premarket evaluation for safety, effectiveness, and quality.
Do GLP-1 medications burn belly fat?
GLP-1 and GIP/GLP-1 medications can significantly reduce overall fat mass, including visceral adipose tissue, as body weight decreases. They do not specifically target one body area like the abdomen.
Can you lose muscle while taking a GLP-1?
Yes. Significant weight loss generally includes some lean-mass reduction. A tirzepatide body-composition substudy found that approximately 75% of weight lost was fat mass and 25% was lean mass. Protein intake, resistance training, and appropriate monitoring should therefore be considered during significant weight reduction.
The Bottom Line
Peptide therapy is not one category with one level of evidence.
Some peptide-based medications have transformed obesity treatment.
Semaglutide, tirzepatide, and liraglutide have undergone extensive clinical testing and received FDA approval for chronic weight management in appropriate patients.
Setmelanotide can produce meaningful weight loss, but it is intended for specific forms of obesity.
Tesamorelin can reduce abdominal fat in HIV-associated lipodystrophy, but it is not a general weight-loss treatment.
Meanwhile, compounds such as AOD-9604, CJC-1295, ipamorelin, and BPC-157 should not be placed in the same evidence category simply because they are called peptides.
And retatrutide, despite highly promising clinical results, remains investigational as of September 2026.
The goal should not be chasing whichever peptide is trending this month.
The goal should be identifying the safest, best-supported treatment for your physiology while protecting muscle, nutrition, metabolic health, and long-term results.
If you are considering medical weight loss or peptide-based therapy, 1st Optimal can help evaluate your metabolic health, goals, labs, and treatment options to build a strategy based on your individual needs.
Medical Disclaimer
This article is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Prescription weight-management medications require evaluation and supervision by a qualified healthcare professional. FDA approvals, indications, warnings, and regulatory policies can change. Individual results vary.
